Who uses BD Rhapsody?
Rhapsody captures single cells in tiny wells on a cartridge and can read each cell's RNA together with its surface proteins. It's made by BD Biosciences, part of Waters. 97 bioRxiv and medRxiv preprints since April 2025 say they used Rhapsody, 31 in the last 6 months. Updated daily (as of Nov 16)
Is Rhapsody use still growing?
Too few to tell: 31 preprints used Rhapsody in Jun–Nov 2026, and under 25 in Jun–Nov 2025.
The last bar is the quarter so far. The % over each year compares it with the year before, as a share of all preprints.
How does Rhapsody compare with other single-cell platforms?
Rhapsody is third, with 3% of their uses in Jun–Nov 2026, up from 2% the year before. Chromium leads with 91%.
Which institutions use Rhapsody most?
The institutions using Rhapsody most are Heinrich Heine University Düsseldorf, German Center for Neurodegenerative Diseases and Fred Hutchinson Cancer Center.
Institutions
Heinrich Heine University Düsseldorf3
German Center for Neurodegenerative Diseases3
Fred Hutchinson Cancer Center2
University of Massachusetts Chan Medical School2
The University of Tokyo2
Where the labs are
The lab's institution and country are the corresponding author's.
Latest preprints using Rhapsody
Who started using Rhapsody recently?
22 institutions posted their first preprint using Rhapsody since April 2025 in the last 6 months, including Mayo Clinic, Pediatric Research Institute Città della Speranza and Ghent University Hospital.
Mayo ClinicSep 23, 2026
- Pediatric Research Institute Città della SperanzaJun 19, 2026
Ghent University HospitalJun 26, 2026
Poznan University of Life SciencesJul 13, 2026
Biogipuzkoa Health Research InstituteJul 18, 2026
National Centre for Asbestos Related DiseasesJul 30, 2026
Huashan HospitalAug 5, 2026
Case Western Reserve UniversityAug 10, 2026
Cancer Research Center Cologne-EssenAug 21, 2026
Duke UniversityAug 24, 2026
An institution counts as new when its first preprint using Rhapsody since April 2025 was posted in the last 6 months; the date is that first preprint.
What do labs use alongside Rhapsody?
Preprints using Rhapsody most often also use NextSeq, NovaSeq X and FACSymphony. The count is preprints using both.
What is Rhapsody used for?
Preprints using Rhapsody are most often in immunology, cancer biology and cell biology.
Fields
Immunology 46Cancer biology 12Cell biology 9Developmental biology 5Microbiology 5Plant biology 3
Where the work was published
- Frontiers in Immunology2
- Nature Plants1
- eLife1
- Communications Biology1
- Cytotherapy1
- PLOS Pathogens1
How we count which preprints use each platform
An AI model reads each preprint in full — its text, its tables and its supplementary files — and lists the products the authors used. A preprint counts for a platform when that record says the lab used it in this work, not when it only analyzed data others made with it or only mentioned it. Each preprint counts once, by its first version, if it was first posted on bioRxiv or medRxiv in April 2025 or later. We read new preprints within days of posting, so the newest ones (through Nov 16, 2026) are already counted, but those days are not complete yet. Six-month counts and growth figures stop at Nov 12, 2026, the last day nearly every preprint has been read, and charts draw a quarter that is still being counted in a paler color. A preprint that used two platforms counts for both. Each title links to the preprint on bioRxiv or medRxiv; we show no preprint text and no author names. Updated daily, most recently on Nov 16, 2026.